I met with Dr. Kashif Shafique of the University of Glasgow who was the senior author of a research poster presented at the meeting. He and his colleagues look at the relationship between systemic inflammation and prostate cancer survival.

Since there is some evidence that pre-treatment of systemic inflammation in men may be associated with changes survival in men with prostate cancer they decided to examine this information from the Glasgow Inflammation Study to evaluate this evidence.

The researchers said that since it is unclear whether this evidence is independent of the gleason grade and stage of the diagnosed prostate cancer they decided to investigated the role of inflammation-based prognostic scores; the modified Glasgow Prognostic Score (mGPS) and Neutrophil Lymphocyte Ratio (NLR) and their associations